Warren B Logge1, Richard W Morris2, Andrew J Baillie3, Paul S Haber4,5, Kirsten C Morley4. 1. Discipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Lv 6, King George V Building, 83-117 Missenden Rd, Camperdown, NSW, 2050, Australia. warren.logge@sydney.edu.au. 2. Central Clinical School, Faculty of Medicine and Health, & Centre for Translational Data Science, University of Sydney, Sydney, NSW, Australia. 3. Faculty of Health Sciences, University of Sydney, Sydney, NSW, Australia. 4. Discipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Lv 6, King George V Building, 83-117 Missenden Rd, Camperdown, NSW, 2050, Australia. 5. Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Abstract
RATIONALE: Baclofen has been shown to effect fMRI alcohol cue reactivity in alcohol dependence, but potential varying effects related to baclofen dose levels have not been examined. OBJECTIVE: This study investigated whether baclofen attenuates craving and alcohol cue-elicited activation in alcohol-dependent treatment seekers, and the relationship between this response and clinical outcomes (Morley et al. 2018; Morley et al. 2013). METHODS:Participants included 30 alcohol-dependent individuals who had receiveddaily baclofen 30 mg (n = 11), 75 mg (n = 8) or placebo (n = 11) for at least 2 weeks. Using functional magnetic resonance imaging (fMRI), we examined alcohol cue-elicited neural activation during a visual alcohol cue reactivity task 120 min following treatment administration, and alcohol cue reactivity and percentage of heavy drinking days (% HDD) associations were assessed. RESULTS: Both baclofen-treated groups reported fewer post-scan % HDD when compared to the placebo-treated group, but no subjective craving group differences were found. Increased alcohol cue-elicited activation was seen in placebo compared to the 75 mg/day baclofen participants in two clusters spanning prefrontal regions implicated in cue reactivity, chiefly frontal regions (i.e., frontal and precentral gyri, anterior cingulate cortex), but no observed alcohol cue reactivity differences between placebo and 30 mg/day baclofen groups. Post-scan % HDD was positively correlated with increased alcohol cue-elicited activation in a cluster encompassing the bilateral caudate nucleus and dorsal anterior cingulate cortex when comparing placebo versus 75 mg/day baclofen groups, and several clusters including prefrontal and mesolimbic regions when comparing placebo versus 30 mg/day baclofen groups. CONCLUSIONS:Baclofen administration attenuates alcohol cue-elicited activation and reduced the association in baclofen-treated participants between increased activity in key drug cue reactivity regions and higher post-scan % HDD observed in placebo-treated participants, suggesting a dose-specific response effect that may lead to reduced heavy drinking in chronic alcohol-dependent individuals. TRIAL REGISTRATION: ClinicalTrials.gov , NCT01711125, https://clinicaltrials.gov/ct2/show /NCT01711125.
RCT Entities:
RATIONALE: Baclofen has been shown to effect fMRI alcohol cue reactivity in alcohol dependence, but potential varying effects related to baclofen dose levels have not been examined. OBJECTIVE: This study investigated whether baclofen attenuates craving and alcohol cue-elicited activation in alcohol-dependent treatment seekers, and the relationship between this response and clinical outcomes (Morley et al. 2018; Morley et al. 2013). METHODS:Participants included 30 alcohol-dependent individuals who had received daily baclofen 30 mg (n = 11), 75 mg (n = 8) or placebo (n = 11) for at least 2 weeks. Using functional magnetic resonance imaging (fMRI), we examined alcohol cue-elicited neural activation during a visual alcohol cue reactivity task 120 min following treatment administration, and alcohol cue reactivity and percentage of heavy drinking days (% HDD) associations were assessed. RESULTS: Both baclofen-treated groups reported fewer post-scan % HDD when compared to the placebo-treated group, but no subjective craving group differences were found. Increased alcohol cue-elicited activation was seen in placebo compared to the 75 mg/day baclofenparticipants in two clusters spanning prefrontal regions implicated in cue reactivity, chiefly frontal regions (i.e., frontal and precentral gyri, anterior cingulate cortex), but no observed alcohol cue reactivity differences between placebo and 30 mg/day baclofen groups. Post-scan % HDD was positively correlated with increased alcohol cue-elicited activation in a cluster encompassing the bilateral caudate nucleus and dorsal anterior cingulate cortex when comparing placebo versus 75 mg/day baclofen groups, and several clusters including prefrontal and mesolimbic regions when comparing placebo versus 30 mg/day baclofen groups. CONCLUSIONS:Baclofen administration attenuates alcohol cue-elicited activation and reduced the association in baclofen-treated participants between increased activity in key drug cue reactivity regions and higher post-scan % HDD observed in placebo-treated participants, suggesting a dose-specific response effect that may lead to reduced heavy drinking in chronic alcohol-dependent individuals. TRIAL REGISTRATION: ClinicalTrials.gov , NCT01711125, https://clinicaltrials.gov/ct2/show /NCT01711125.
Entities:
Keywords:
Alcohol use disorder; Baclofen; Cue reactivity; Functional magnetic resonance imaging; GABA; Neuroimaging; Randomised controlled trial
Authors: Anne Beck; Patricia Pelz; Robert C Lorenz; Katrin Charlet; Olga Geisel; Andreas Heinz; Torsten Wüstenberg; Christian A Müller Journal: Eur Neuropsychopharmacol Date: 2018-09-11 Impact factor: 4.600
Authors: Esther M Beraha; Elske Salemink; Anna E Goudriaan; Abraham Bakker; David de Jong; Natasha Smits; Jan Willem Zwart; Dick van Geest; Pieter Bodewits; Tom Schiphof; Harma Defourny; Mirjam van Tricht; Wim van den Brink; Reinout W Wiers Journal: Eur Neuropsychopharmacol Date: 2016-11-11 Impact factor: 4.600
Authors: Roberta Agabio; Julia Ma Sinclair; Giovanni Addolorato; Henri-Jean Aubin; Esther M Beraha; Fabio Caputo; Jonathan D Chick; Patrick de La Selle; Nicolas Franchitto; James C Garbutt; Paul S Haber; Mathis Heydtmann; Philippe Jaury; Anne R Lingford-Hughes; Kirsten C Morley; Christian A Müller; Lynn Owens; Adam Pastor; Louise M Paterson; Fanny Pélissier; Benjamin Rolland; Amanda Stafford; Andrew Thompson; Wim van den Brink; Renaud de Beaurepaire; Lorenzo Leggio Journal: Lancet Psychiatry Date: 2018-11-06 Impact factor: 27.083
Authors: Giovanni Addolorato; Lorenzo Leggio; Anna Ferrulli; Silvia Cardone; Luisa Vonghia; Antonio Mirijello; Ludovico Abenavoli; Cristina D'Angelo; Fabio Caputo; Antonella Zambon; Paul S Haber; Giovanni Gasbarrini Journal: Lancet Date: 2007-12-08 Impact factor: 79.321
Authors: Giovanni Addolorato; Fabio Caputo; Esmeralda Capristo; Marco Domenicali; Mauro Bernardi; Luigi Janiri; Roberta Agabio; Giancarlo Colombo; Gian Luigi Gessa; Giovanni Gasbarrini Journal: Alcohol Alcohol Date: 2002 Sep-Oct Impact factor: 2.826
Authors: Kirsten C Morley; Eva Louie; Tristan Hurzeler; Andrew Baillie; Glenys Dore; Nghi Phung; Paul S Haber Journal: Front Glob Womens Health Date: 2022-03-29
Authors: Bradford Martins; Will Rutland; Joao P De Aquino; Benjamin L Kazer; Melissa Funaro; Marc N Potenza; Gustavo A Angarita Journal: Curr Addict Rep Date: 2022-08-15